THE TRIO TRIAL - A RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING THE EFFECT OF A BIOCOMPATIBLE PERITONEAL DIALYSIS SOLUTION ON RESIDUAL RENAL FUNCTION

被引:17
作者
Sikaneta, Tabo [1 ]
Wu, George [2 ]
Abdolell, Mohamed [3 ]
Ng, Anita [4 ]
Mahdavi, Sara [1 ]
Svendrovski, Anton [5 ]
Tu, Tony [4 ]
Mercer, Trish [2 ]
Tong, Matthew [6 ]
Oreopoulos, Dimitrios [7 ]
Tam, Paul [1 ]
机构
[1] Scarborough Gen Hosp, Dept Nephrol, 3050 Lawrence St E, Scarborough, ON, Canada
[2] Credit Valley Hosp, Dept Med, Mississauga, ON, Canada
[3] Dalhousie Univ, Div Radiol, Halifax, NS, Canada
[4] Kidney Life Sci Inst, Res Dept, Scarborough, ON, Canada
[5] Private Stat Consultants, Toronto, ON, Canada
[6] Princess Margaret Hosp, Med & Geriatr, Hong Kong, Hong Kong, Peoples R China
[7] Univ Hlth Network, Dept Nephrol, Toronto, ON, Canada
来源
PERITONEAL DIALYSIS INTERNATIONAL | 2016年 / 36卷 / 05期
关键词
Peritoneal dialysis; biocompatible PD solutions; residual renal function; peritonitis; OUTCOMES; IMPACT;
D O I
10.3747/pdi.2015.00090
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: Residual renal function (RRF) correlates with mortality and morbidity rates in patients receiving peritoneal dialysis (PD). We examined the effect of a biocompatible PD solution (Gambrosol Trio; Gambro Lundia AB, Lund, Sweden) with lower concentrations of glucose degradation products on rates of decline in RRF. Design, setting, participants, and measurements: Incident patients at 2 centers in Canada and 1 in Hong Kong were randomized (by minimization) in an open-label parallel group trial to receive Gambrosol Trio or standard PD solution (Dianeal; Baxter Healthcare, Mississauga, Canada) for 2 years. Primary outcome was slope of RRF. Secondary outcomes were urine volumes, fluid and nutrition indices, PD and membrane characteristics, peritonitis rates, adverse events, and PD technique survival. Results: Residual renal function declined by 0.132 mL/minute/1.73 m(2)/month in 51 patients allocated to biocompatible, and 0.174 mL/minute/1.73 m(2)/month in 50 patients allocated to standard PD solution (difference 0.042 mL/minute/1.73m(2)/month, p = 0.001). Urine volume, body mass index, normalized protein catabolic rates, and fat mass were higher; total body water, peritoneal ultrafiltration, and D/P creatinine did not differ; and serum phosphate, rates of icodextrin, and automated cycler use were lower with Gambrosol Trio use. There were more peritonitis events with Gambrosol Trio use, while PD technique survival did not differ between groups. Conclusions: The use of the biocompatible PD solution Gambrosol Trio was associated with slower rates of decline in RRF, fluid and nutrition benefits, and increased peritonitis rates.
引用
收藏
页码:526 / 532
页数:7
相关论文
共 15 条
[1]   Impact of new dialysis solutions on peritonitis rates [J].
Ahmad, S. ;
Sehmi, J. S. ;
Ahmad-Zakhi, K. H. ;
Clemenger, M. ;
Levy, J. B. ;
Brown, E. A. .
KIDNEY INTERNATIONAL, 2006, 70 :S63-S66
[2]   Biocompatible peritoneal dialysis solutions: many questions but few answers [J].
Blake, Peter G. ;
Jain, Arsh K. ;
Yohanna, Sechelle .
KIDNEY INTERNATIONAL, 2013, 84 (05) :864-866
[3]  
Cho Y, 2014, COCHRANE DB SYST REV, V3
[4]   The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients [J].
Cho, Yeoungjee ;
Johnson, David W. ;
Badve, Sunil V. ;
Craig, Jonathan C. ;
Strippoli, Giovanni F. M. ;
Wiggins, Kathryn J. .
KIDNEY INTERNATIONAL, 2013, 84 (05) :969-979
[5]   Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes [J].
Cho, Yeoungjee ;
Badve, Sunil V. ;
Hawley, Carmel M. ;
McDonald, Stephen P. ;
Brown, Fiona G. ;
Boudville, Neil ;
Bannister, Kym M. ;
Clayton, Philip A. ;
Johnson, David W. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (09) :1556-1563
[6]  
Diaz-Buxo Jose A, 2013, Adv Perit Dial, V29, P19
[7]   Predictors of survival in anuric peritoneal dialysis patients [J].
Jansen, MAM ;
Termorshuizen, F ;
Korevaar, JC ;
Dekker, FW ;
Boeschoten, E ;
Krediet, RT .
KIDNEY INTERNATIONAL, 2005, 68 (03) :1199-1205
[8]   Effects of Biocompatible versus Standard Fluid on Peritoneal Dialysis Outcomes [J].
Johnson, David W. ;
Brown, Fiona G. ;
Clarke, Margaret ;
Boudville, Neil ;
Elias, Tony J. ;
Foo, Marjorie W. Y. ;
Jones, Bernard ;
Kulkarni, Hemant ;
Langham, Robyn ;
Ranganathan, Dwarakanathan ;
Schollum, John ;
Suranyi, Michael ;
Tan, Seng H. ;
Voss, David .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (06) :1097-1107
[9]   Change in Body Composition in Accordance With Residual Renal Function in Patients on Peritoneal Dialysis [J].
Kang, Seok Hui ;
Cho, Kyu Hyang ;
Park, Jong Won ;
Yoon, Kyung Woo ;
Do, Jun Young .
JOURNAL OF RENAL NUTRITION, 2013, 23 (06) :438-444
[10]   Importance of residual renal function in continuous ambulatory peritoneal dialysis:: Its influence on different parameters of renal replacement treatment [J].
López-Menchero, R ;
Miguel, A ;
García-Ramón, R ;
Pérez-Contreras, J ;
Girbés, V .
NEPHRON, 1999, 83 (03) :219-225